Apparently bad - and somewhat puzzling - early news from the Phase III trial with its personalized kidney cancer vaccine sent Antigenics Inc.’s stock reeling. The company has suspended part two of the study while analyzing top-line data from the first part, and planning more changes at the firm to reduce the burn rate. (BioWorld Today) Read More
